Eleven Biotherapeutics Inc. (Nasdaq: EBIO) presented new data from post hoc analyses on the influence of Interleukin Genetics' IL-1 genetic patterns on response to isunakinra in patients with severe allergic conjunctivitis and severe dry eye. Shares of the biopharmaceutical rose 19 cents to $1.21.